ENDOSSEOUS BLADE IMPLANTS SHOULD REMAIN IN CLASS III, FDA PANEL SAYS; AGENCY OPEN TO FUTURE DOWNCLASSIFICATION; ROOT FORM IMPLANTS, ABUTMENTS TO CLASS II
This article was originally published in The Gray Sheet
FDA is open to receiving additional data to support the downclassification of blade-type endosseous implants and is not planning to call for premarket approval applications for the devices in the near future, agency staffers say. Blade implants are the only type of endosseous devices that FDA should keep in Class III, FDA's Dental Products Advisory Panel recommended at a Jan. 13 meeting in Rockville, Maryland.
You may also be interested in...
FDA export rule stayed: Agency will delay implementation of the final rule on export notification and recordkeeping requirements until June 19, according to a 1May 14 Federal Register notice. Issued in December 2001, the rule was scheduled to take effect in March (2"The Gray Sheet" Dec. 24, 2001, p 4). Three petitions and one letter stating that "certain parties would be unable to comply by the original March 19 effective date and that some parties were confused as to the final rule's applicability to certain products," prompted the agency's decision to stay the rule. The rule implements provisions of FDA's Export Reform & Enhancement Act of 1996...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.